Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TAK-831 in Healthy Subjects
NCT02566759Phase 1Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of luvadaxistat in schizophrenia and cerebellar ataxia (CA) (14 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event, Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests and 2 more. Started Sep 2015; status: terminated.
02
Drugs
luvadaxistat
03
Conditions
schizophreniacerebellar ataxia (CA)
Beyond the preview
Go deeper on NCT02566759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566759.